Phase 1 Malignancies Clinical Trials
95 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 95 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 1Phase 2
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Hematologic MalignanciesHIV
National Cancer Institute (NCI)265 enrolled1 locationNCT05470491
Recruiting
Phase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1Phase 2
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Myeloid Malignancies
M.D. Anderson Cancer Center42 enrolled1 locationNCT06930651
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 1
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting
Phase 1
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Hematologic NeoplasmsHematologic Malignancies
National Cancer Institute (NCI)155 enrolled1 locationNCT07162038
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Solid Tumor MalignanciesCRC (Colorectal Cancer)KRAS G12C Mutation+1 more
Kumquat Biosciences Inc.140 enrolled11 locationsNCT06720987
Recruiting
Phase 1
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting
Phase 1Phase 2
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc255 enrolled1 locationNCT07299747
Recruiting
Phase 1Phase 2
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc310 enrolled5 locationsNCT07136779
Recruiting
Phase 1
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Hematologic MalignanciesSolid Malignancies
Immunome, Inc.117 enrolled13 locationsNCT06823167
Recruiting
Phase 1Phase 2
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Lymphoid Malignancies
AVM Biotechnology Inc144 enrolled11 locationsNCT04329728
Recruiting
Phase 1
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Solid TumorsHematologic Malignancies
Incyte Corporation280 enrolled22 locationsNCT07195916
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor MalignanciesEGFREGFR Positive Solid Tumors
Vir Biotechnology, Inc.450 enrolled4 locationsNCT06960395
Recruiting
Phase 1
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
AMLMyelodysplastic SyndromesCML+3 more
University of Alabama at Birmingham50 enrolled1 locationNCT06047886
Recruiting
Phase 1
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
Advanced Hematologic Malignancies
Sumitomo Pharma America, Inc.8 enrolled2 locationsNCT07444268
Recruiting
Phase 1
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
IDH1-Mutated Malignancies
Servier Bio-Innovation LLC30 enrolled19 locationsNCT07006688
Recruiting
Phase 1
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356